All data are based on the daily closing price as of January 23, 2025
s

Synmosa Biopharma

4114.TWO
1.02 USD
0.01
+0.99%

Overview

Last close
1.02 usd
Market cap
432.09M usd
52 week high
1.20 usd
52 week low
0.98 usd
Target price
1.1 usd

Valuation

P/E
19.6471
Forward P/E
N/A
Price/Sales
2.7266
Price/Book Value
1.9974
Enterprise Value
455.86M usd
EV/Revenue
2.7808
EV/EBITDA
13.6355

Key financials

Revenue TTM
158.15M usd
Gross Profit TTM
67.18M usd
EBITDA TTM
29.91M usd
Earnings per Share
0.05 usd
Dividend
N/A usd
Total assets
383.43M usd
Net debt
46.32M usd

About

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms. It also offers contract manufacturing services. In addition, it exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was incorporated in 1980 and is based in Taipei, Taiwan.
  • Symbol
    4114.TWO
  • Exchange
    TWO
  • Isin
    TW0004114004
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Banson Lin
  • Headquarter
    Taipei
  • Web site
    https://www.synmosa.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top